Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Open Gastroenterology"
DOI: 10.1136/bmjgast-2023-001105
Abstract: Background We aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease (IBD) centre. Methods All adult… read more here.
Keywords: intravenous subcutaneous; switching patients; cost; costs switching ... See more keywords